MINDMAZE THERAPEUTICS-ADR (RLFTY:OTCMKTS)
$0 None (None%)
Analysed MINDMAZE THERAPEUTICS-ADR (RLFTY:OTCMKTS) News Sources
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
29-10-2025
yahoo.com
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
14-11-2025
yahoo.com
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
15-12-2025
yahoo.com
MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics
23-12-2025
yahoo.com
What is the current price of MINDMAZE THERAPEUTICS-ADR (RLFTY:OTCMKTS)?
The current price of MINDMAZE THERAPEUTICS-ADR (RLFTY:OTCMKTS) is $0.
MINDMAZE THERAPEUTICS-ADR (RLFTY:OTCMKTS) absolute price change since previous trading day?
The absolute price change of MINDMAZE THERAPEUTICS-ADR (RLFTY:OTCMKTS) since the previous trading day is $None.
MINDMAZE THERAPEUTICS-ADR (RLFTY:OTCMKTS) percentage price change since previous trading day?
The percentage price change of MINDMAZE THERAPEUTICS-ADR (RLFTY:OTCMKTS) since the previous trading day is None%.
What is the most recent average sentiment score for MINDMAZE THERAPEUTICS-ADR (RLFTY:OTCMKTS)?
The most recent average sentiment score for MINDMAZE THERAPEUTICS-ADR (RLFTY:OTCMKTS) is 79 out of 100.
What is the most recent average sentiment for MINDMAZE THERAPEUTICS-ADR (RLFTY:OTCMKTS)?
The most recent sentiment for MINDMAZE THERAPEUTICS-ADR (RLFTY:OTCMKTS) is .
SEC-8K** Filing Available For MINDMAZE THERAPEUTICS-ADR (RLFTY:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.